Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study
Int J Dermatol
.
2020 Nov;59(11):e431-e433.
doi: 10.1111/ijd.14987.
Epub 2020 Jun 9.
Authors
Suzette M Arias-Mejias
1
,
Enrica Quattrocchi
1
,
Dennie Tempel
2
,
Mark Luna-Vargas
2
,
Jeff Chen
2
,
Dennis H Murphree
3
,
Sandra Gjorgova Gjeorgjievski
4
,
Julia S Lehman
5
,
Alina G Bridges
5
,
Jvalini Dwarkasing
2
,
Alexander Meves
1
Affiliations
1
Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
2
SkylineDx B.V., Rotterdam, the Netherlands.
3
Division of Digital Health Sciences, Mayo Clinic, Rochester, MN, USA.
4
Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
5
Division of Dermatopathology and Cutaneous Immunopathology, Mayo Clinic, Rochester, MN, USA.
PMID:
32516450
PMCID:
PMC7687092
DOI:
10.1111/ijd.14987
No abstract available
Publication types
Letter
MeSH terms
Gene Expression
Humans
Melanoma* / genetics
Pilot Projects
Prognosis
Risk Assessment
Skin Neoplasms* / genetics
Grants and funding
K08 CA215105/CA/NCI NIH HHS/United States
UL1 TR000135/TR/NCATS NIH HHS/United States
CA215105/CA/NCI NIH HHS/United States
UL1TR000135/TR/NCATS NIH HHS/United States